4//SEC Filing
Baynes Roy D. 4
Accession 0001415889-25-013496
CIK 0001438533other
Filed
May 15, 8:00 PM ET
Accepted
May 16, 7:00 PM ET
Size
7.4 KB
Accession
0001415889-25-013496
Insider Transaction Report
Form 4
Baynes Roy D.
Director
Transactions
- Award
Common Stock
2025-05-15+6,500→ 37,500 total - Award
Stock option (right to buy)
2025-05-15+19,500→ 19,500 totalExercise: $21.15From: 2026-05-15Exp: 2035-05-15→ Common Stock (19,500 underlying)
Footnotes (2)
- [F1]Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.
- [F2]The equity award vests over a one year period.
Documents
Issuer
Travere Therapeutics, Inc.
CIK 0001438533
Entity typeother
Related Parties
1- filerCIK 0001680739
Filing Metadata
- Form type
- 4
- Filed
- May 15, 8:00 PM ET
- Accepted
- May 16, 7:00 PM ET
- Size
- 7.4 KB